Clinical trials: Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy, Diabetic Retinopathy
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.
In prolifertive diabetic retinopathy (PDR) eyes with bleeding known as vitreous hemorrhage (VH) requiring a surgical procedure to remove the vitreous, called a vitrectomy, we will determine if the benefit and safety of adding a…
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
- Trial name
- 4 PORT (NCT07864480)
- Testing
- PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Southeast Retina Center, Georgia
Diabetic Retinopathy, Non Proliferative Diabetic Retinopathy
Randomized, Controlled Study to Investigate the 12-month Efficacy and Safety of Resveratrol Vitamin Supplements in Patients With Non-proliferative Diabetic Retinopathy Without Center Involved Diabetic Macular Edema (REVOLUTION Study)
This randomized, controlled study aims to investigate the efficacy and safety of resveratrol-containing vitamin supplements in patients with non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular…
- Conditions
- Diabetic Retinopathy, Non Proliferative Diabetic Retinopathy, Prospective Study
- Trial name
- REVOLUTION (NCT07868458)
- Testing
- Resveratrol-Containing Vitamin Supplement
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Athens
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period…
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema
- Trial name
- NCT06599684
- Testing
- INV-102
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Invirsa, Inc.
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR).
- Trial name
- NCT06770933
- Testing
- VX-01
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Vantage Biosciences Ltd
Proliferative Diabetic Retinopathy (PDR)
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser.
- Trial name
- AP (NCT06790784)
- Testing
- Vitrectomy, Endolaser, Faricimab
- Where
- 34 sites in United States
- Volunteers
- 426 people
- Sponsor
- Jaeb Center for Health Research
Proliferative Diabetic Retinopathy (PDR)
Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathy
To evaluate the effects of PRP as monotherapy or with combination of intravitreal Ranibizumab injection on microvascular density changes of the macula of eyes with PDR using OCTA
- Trial name
- PRP VS PRP&RZB (NCT07819253)
- Testing
- Ranibizumab 0.5 mg, laser photocoagulation (PRP)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Aswan University
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Qlaris Bio, Inc.
Non-Proliferative Diabetic Retinopathy
To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR
This study is planned to evaluate the efficacy and safety of combination therapy with B55R1 and B55R2 compared to B55R1 monotherapy in patients with non-proliferative diabetic retinopathy (NPDR).
- Trial name
- NCT07230184
- Testing
- B55R1 and B55R2
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- AJU Pharm Co., Ltd.
Proliferative Diabetic Retinopathy
Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia
The purpose of this study was to compare two different anesthesia methods for pain control during panretinal photocoagulation (PRP), a type of laser surgery that treats proliferative diabetic retinopathy (PDR).
- Trial name
- NCT07640256
- Testing
- Peribulbar anesthesia with 0.5% bupivacaine and 2% lidocaine, Tetracaine 5% drops
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Proliferative Diabetic Retinopathy (PDR)
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
The goal of this clinical trial is to learn whether early microincision vitrectomy surgery (MIVS) can improve retinal neovascularization outcomes compared to standard pan-retinal photocoagulation (PRP) in patients with early…
- Trial name
- NCT07586787
- Testing
- Microincision Vitrectomy Surgery, Panretinal Photocoagulation
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- Xiamen Ophthalmology Center Affiliated to Xiamen University
Non-Proliferative Diabetic Retinopathy
Safety and Efficacy of Faricimab in Patients With NPDR
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
- Trial name
- MAGIC (NCT05681884)
- Testing
- Faricimab
- Where
- 16 sites in United States
- Volunteers
- 179 people
- Sponsor
- Greater Houston Retina Research
Proliferative Diabetic Retinopathy (PDR)
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
- Trial name
- HERO (NCT07118670)
- Testing
- Aflibercept 8mg
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Edward Wood, MD
Non-Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
The purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy.
- Trial name
- HELIOS-3 (NCT07235085)
- Testing
- Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
- Where
- United States
- Volunteers
- 930 people
- Sponsor
- Ocular Therapeutix, Inc.
Proliferative Diabetic Retinopathy
Genetic Markers and Proliferative Diabetic Retinopathy
Type 2 Diabetes (TD2) is the leading cause of new cases of preventable blindness in these countries (and the gold-standard treatment, laser photocoagulation has proven to be effective in preventing vision loss at the end stage of…
- Trial name
- REDIAGEN (NCT02879422)
- Testing
- genetic analysis
- Where
- France
- Volunteers
- 302 people
- Sponsor
- CHU de Reims
Proliferative Diabetic Retinopathy, Photocoagulation Burn to Retina
New Pattern of Retinal Laser Treatment for PDR
The objective of the study is to evaluate the efficacy of a new pattern of argon-laser in treating patients with proliferative diabetic retinopathy (PDR).
- Trial name
- NCT07315802
- Testing
- A new pattern of retinal laser
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Epiretinal Membrane, Macular Hole
UNITY VCS Vitreoretinal Surgery
This purpose of this study is to compare the safety and effectiveness of two eye surgery systems-UNITY VCS and CONSTELLATION-in treating adults with vitreoretinal diseases or disorders.
- Conditions
- Epiretinal Membrane, Macular Hole, Visually Significant Vitreous Floater, Vitreomacular Traction
- Trial name
- NCT07054281
- Testing
- UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vision System, Vitreoretinal ophthalmic surgery
- Where
- 8 sites in United States
- Sponsor
- Alcon Research
NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2
Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures (CHART)
To identify biomarkers, obtained using non-invasive procedures, that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in Non…
- Conditions
- NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2, Retinal Disease
- Trial name
- CHART (NCT04636307)
- Testing
- Biomarkers
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 202 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in…
- Trial name
- NEXUS (NCT07259928)
- Testing
- ANXV
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Annexin Pharmaceuticals AB
Non-proliferative Diabetic Retinopathy (NPDR)
Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy
This study is a single-center, open-label, parallel-controlled trial, scheduled to commence in October 2025 at the outpatient and inpatient departments of Shanghai General Hospital.
- Trial name
- NCT07236645
- Testing
- Ginaton (ginkgo biloba extract tablet), standard treatment
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine